TECH

Bio-Techne is a high-quality life-sciences tools franchise: 64.8% gross margins, $288M of operating cash flow on $1.22B of revenue, and a clean balance sheet ($1.92B equity, only $12.5M of current debt against $162M cash). The Protein Sciences segment ($870M, the bulk of the business) delivered the 5% organic growth that management called out, and adjusted net earnings rose 8% on 'favorable volume leverage.' This is a durable, recurring-reagent business with two-segment scale and ongoing M&A optionality (Lunaphore closed in FY24; Wilson Wolf roll-up due by end of 2027).

But the GAAP picture is ugly and the valuation does not forgive it. Net income fell from $168M to $73.4M (-56%), operating income halved to $102M, and diluted EPS of $0.46 implies a 153.7x P/E at $70.70. Management attributes the earnings collapse to 'a non-recurring loss on an arbitration award, impairment of assets held-for-sale, and restructuring' — items that are real cash and reputational costs even if framed as one-time. The 244% surge in buybacks ($276M) drained retained earnings 19.6% and total assets 5.4%; capital is being returned aggressively into a stock trading at a premium multiple. ROE of 3.8% is anemic for a company of this quality precisely because GAAP earnings have been squeezed.